8 August 2025

Osteopore embarks on clinical study with Universiti Malaya for socket healing in dental surgery

Highlights

- **Osteopore embarks on a clinical study with Universiti Malaya for secondary socket healing in third molar surgery in 18 patients.**
- **The study aims to compare the effects of Osteopore's polycaprolactone membrane with collagen membrane at the third molar surgical site of the lower jaw.**
- **Ethics approval has been obtained, with patient recruitment expected to commence immediately.**

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce that it has embarked on a clinical study with the Universiti Malaya (UM) for secondary socket healing in third molar surgery.

The Universiti Malaya is a public research university located in Kuala Lumpur, Malaysia. UM is ranked consistently as the No. 1 university in Malaysia and among the top 3 universities in Southeast Asia – UM is currently ranked 58th in the QS World University Rankings published on 19 June 2025[1].

[1] https://www.topuniversities.com/world-university-rankings

The university has also graduated five prime ministers of Malaysia, and other political, business, and cultural figures of national prominence.

The clinical study will be spearheaded by Dr. Tan Chuey Chuan from the Department of Oral and Maxillofacial Clinical Sciences at UM. Dr. Tan is also a lecturer at the department. She obtained her Doctor of Dental Surgery (DDS) from Universiti Sains Malaysia (USM), was awarded the Membership of the Faculty of Dental Surgery by the Royal College of Surgeons of Edinburgh (MFDS RCS(Ed)), and post-graduate Master of Clinical Dentistry (OMFS) from UM.

The clinical study aims to compare the wound healing effects of Osteopore's polycaprolactone (PCL) membrane against collagen membrane at the third molar surgical site of the lower jaw.

The study, which has obtained ethics approval, expects to recruit a total of 18 participants with a post-procedure follow-up period of 6 months for all participants.

The surgical removal of impacted third molars of the lower jaw is a commonly performed procedure. However, it is often associated with post-operative morbidities such as pain and facial swelling. In addition, it may result in compromised periodontal health of the adjacent second molar.

While collagen membranes are commonly used for socket healing in such procedures, its degradation profile may result in early loss of barrier function that impedes bone healing[2].

Osteopore's PCL membrane offers the distinct advantage of gradual degradation over a longer period of time, thereby enhancing the barrier function of a membrane to facilitate bone healing.

[2] Mizraji et al., https://doi.org/10.1111/prd.12502.

Commenting on embarking on this clinical study with UM, CEO Dr Yujing Lim, said:

"We are delighted that Universiti Malaya recognises the value of our dental membrane in supporting socket healing."

"This study provides us with a great opportunity to benchmark our dental innovation against current practice", said Dr. Lim.

Commenting on the clinical study with Osteopore , Dr. Tan Chuey Chuan, said:

"Collagen membranes are widely available as a material, however Osteopore's 3D printed membrane offers a potentially superior option for us to consider as clinicians for bone healing and regeneration, with the additional benefits of not being from an animal source as well as allowing easy customisation for our patients."

"We look forward to getting the first patient recruited to the study", said Dr. Tan.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Mark Leong
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.